Stem Cell Transplant for Myelodysplastic Syndrome
What You Need to Know Before You Apply
What is the purpose of this trial?
This is a single center phase II study of allogeneic stem cell transplantation in MDS who are unlikely to benefit from conventional therapy. Patients will undergo standard allogeneic stem cell transplant protocol following standard Flu/TBI 800 conditioning, PBSC transplant, and GVHD prophylaxis with PTCy and tacrolimus.
Who Is on the Research Team?
Ronald Paquette, MD
Principal Investigator
Cedars-Sinai Medical Center
Are You a Good Fit for This Trial?
This trial is for people with myelodysplastic syndrome (MDS) who are not expected to benefit from standard treatments. Participants must be healthy enough for a stem cell transplant and meet other medical requirements set by the study team.Inclusion Criteria
Exclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- Allogeneic Stem Cell Transplant
Trial Overview
The study tests allogeneic stem cell transplants in MDS patients after preparing their bodies with fludarabine and total body irradiation (800 cGy). Patients receive donor cells, plus medications to prevent rejection and complications.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Find a Clinic Near You
Who Is Running the Clinical Trial?
Ronald Paquette
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.